Single domain antibody against serpin a12 and use thereof
A single domain antibody targeting Serpin A12 addresses the challenges of antibody size and stability by providing high affinity and therapeutic efficacy for treating bone diseases, specifically reducing inflammation and improving bone function in conditions like degenerative arthritis.
Patent Information
- Application Number
- PCT/KR2024/095872
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-30
- Filing Date
- 2024-05-30
- Publication Date
- 2024-12-05
AI Technical Summary
Current antibody drugs face challenges in targeting cell surfaces or water-soluble targets due to their large size and stability issues, limiting their therapeutic applications, particularly for Serpin A12, which is associated with obesity and glucose metabolism, with insufficient drug development efforts.
Development of a single domain antibody (sdAb) specifically binding to Serpin A12, comprising specific amino acid sequences for CDR and FR regions, which can be used as a monomeric or multimeric form, fused with an Fc fragment, and produced through expression vectors in host cells, offering high affinity and stability for therapeutic use.
The sdAb effectively binds to Serpin A12, providing therapeutic benefits for bone diseases by reducing inflammation and improving bone function, as demonstrated by its ability to inhibit degenerative arthritis in mouse models.
Smart Images

Figure KR2024095872_05122024_PF_FP_ABST
Abstract
Description
Single domain antibodies to SERPIN A12 and uses thereof
[0001] The present invention relates to single domain antibodies against Serpin A12 and uses thereof.
[0002] The antibody drug sector is the most actively developing, accounting for over 50% of total biopharmaceutical market sales as of 2019. Notably, immune checkpoint inhibitors, such as Keytruda (pembrolizumab, Merck), Opdivo (nivolumab, BMS / Ono), Yervoy (ipilimumab, BMS / Ono), and Tecentriq (atezolizumab, Roche), accounted for 47.2% of the total sales of the top 10 products during the same period, demonstrating that antibody anticancer drugs are driving the growth of antibody drugs.
[0003] Despite the growth and technological advancements in the antibody drug field, the development of new antibody drugs still presents many technical challenges due to the inherent characteristics of antibodies. For example, their large size makes membrane penetration difficult, limiting therapeutic development targets to cell surface or soluble targets. Furthermore, more advanced antibody formulations, such as antibody fragments (scFv: single-chain variable fragment, Fab: Fab region containing the antibody variable region, etc.), still face challenges due to low stability.
[0004] Among these, nanobodies, which have recently begun to be developed in the therapeutic and diagnostic fields, are attracting attention as a new alternative that can overcome limitations in the development of existing antibody therapeutics based on their small size and high stability.
[0005] A single-domain antibody (sdAb), also known as a nanobody, is an antibody fragment composed of a single monomeric variable domain. Currently, the only single-domain antibody drug approved by the US FDA is Cablivi (Caplacizumab), a treatment for thrombotic thrombocytopenic purpura (TTP) developed by Ablynx. However, many research and developments are underway, including the recent approval of a single-domain antibody anti-TNFα treatment in Japan in March 2021. In particular, it can be utilized not only by binding to the existing IgG type, but also by conjugating small molecule substances (chemicals) with antibody-drug conjugates (ADCs). It is also known to have various applications, such as binding to vesicles such as liposomes and utilizing radioisotopes.
[0006] Serpin A12 (Ser A12) is a glycoprotein, a class A member of the serine protease inhibitor (serpin) family, and is encoded by the SERPINA12 gene in humans. First discovered in 2005, Serpin A12 is expressed in the visceral and subcutaneous adipose tissue of obese individuals and is known to be associated with obesity, glucose metabolism, and insulin resistance. Given this background, its potential as a drug target needs to be considered, but sufficient drug development targeting this protein has not yet been achieved. The present invention was completed by developing a single-domain antibody against Serpin A12.
[0007] An object of the present invention is to provide a single domain antibody (sdAb) against Serpin A12 and uses thereof.
[0008] In order to achieve the object of the present invention, the present invention provides an antibody or antigen-binding fragment thereof comprising a single domain antibody (sdAb) that specifically binds to SERPIN A12,
[0009] The present invention provides an antibody or antigen-binding fragment thereof, wherein the sdAb comprises a CDR1 comprising an amino acid sequence represented by SEQ ID NO: 2; a CDR2 comprising an amino acid sequence represented by SEQ ID NO: 3; and a CDR3 comprising an amino acid sequence represented by SEQ ID NO: 4.
[0010] In addition, the sdAb may be an sdAb comprising FR1 consisting of an amino acid sequence represented by SEQ ID NO: 5; FR2 consisting of an amino acid sequence represented by SEQ ID NO: 6; FR3 consisting of an amino acid sequence represented by SEQ ID NO: 7; and FR4 consisting of an amino acid sequence represented by SEQ ID NO: 8.
[0011] More specifically, it may be an sdAb having a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4 based on the above-mentioned sequence.
[0012] In some implementations, it may be an sdAb represented by SEQ ID NO: 1.
[0013] - Sequence number 1:
[0014] QVQLAESGGGLVQSGGSLRLSCTDSGESLGYYAVGWFRQAPGKEREGVSWISSTGGTTDYADSVKDRFTISRDNANDKVYLQMNSLKHEDTGVYYCAAQIRETRGLWEDYDFWGQGTQVTVSS
[0015] In one aspect of the present invention, the sdAb may comprise at least one amino acid substitution, wherein the at least one amino acid substitution may be a conservative substitution, or may be a substitution of an amino acid with a non-genetically encoded amino acid or a synthetic amino acid.
[0016] In one aspect of the present invention, a heavy chain-only antibody (HCAb) is provided in which the sdAb is fused to an Fc fragment.
[0017] In one aspect of the present invention, the HCAb may be monomeric or multimeric.
[0018] In one aspect of the present invention, the sdAb can be fused to the Fc fragment via a peptide linker, and the Fc fragment can be human IgG1, IgG2, IgG3 or IgG4.
[0019] In one aspect of the present invention, the HCAb may comprise at least one amino acid substitution, wherein the at least one amino acid substitution may be a conservative substitution, or may be a substitution of an amino acid with a non-genetically encoded amino acid or a synthetic amino acid.
[0020] The present invention also provides a nucleic acid molecule encoding the antibody or antigen-binding fragment thereof.
[0021] Additionally, the present invention provides an expression vector comprising the nucleic acid molecule.
[0022] In addition, the present invention provides a host cell transformed with the expression vector.
[0023] The present invention also provides a method for producing an antibody or an antigen-binding fragment thereof, comprising the steps of (a) culturing the host cell under conditions that allow the antibody to be expressed; and (b) recovering the expressed antibody or antigen-binding fragment thereof.
[0024] In addition, the present invention provides a pharmaceutical composition for preventing or treating bone disease, containing the antibody or an antigen-binding fragment thereof, or the antibody conjugate as an active ingredient.
[0025] More specifically, the bone disease may be at least one selected from the group consisting of osteoporosis, periodontal disease, rheumatoid arthritis, multiple myeloma, degenerative arthritis, inflammatory alveolar bone resorptive disease, and inflammatory bone resorptive disease.
[0026] In one aspect of the present invention, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier.
[0027] In addition, the present invention
[0028] (i) a step of contacting a sample with the antibody or antigen-binding fragment thereof; and
[0029] (ii) a method for detecting SERPIN A12 or determining the amount of SERPIN A12 in a sample, comprising the step of detecting the formation of a complex between the antibody or antigen-binding fragment thereof and SERPIN A12 or determining the amount of the complex.
[0030] In the present invention, a single domain antibody that specifically binds to SERPIN A12 has high affinity for SERPIN A12 and exhibits effects of recovering inflammation and improving bone function in bone diseases, and thus has high utility in various bone diseases.
[0031] Figure 1 shows the results of ELISA to confirm the binding ability of a nanobody produced according to one embodiment of the present invention to Serpin A 12.
[0032] Figure 2 shows the results of confirming the antigen-antibody binding affinity of a nanobody produced according to one embodiment of the present invention through OCTET.
[0033] Figure 3 is a schematic diagram of injection of Serpina12 nanobody (10 ug / 10 ul) into the knee joint cavity of mice induced with degenerative arthritis, and the results of confirming the arthritis inhibition ability of Serpina12 nanobody.
[0034] Figure 4 is a schematic diagram of injection of Serpina1 2 nanobody into the knee joint cavity of mice induced with degenerative arthritis, and the results of confirming the arthritis inhibition ability of Serpina12 nanobody (5 ug / 10 ul and 25 ug / 10 ul).
[0035] Figure 5 is the result of confirming the raw data shown in Figure 4.
[0036] Hereinafter, embodiments of the present invention will be described in detail so that those skilled in the art can easily implement the invention. These embodiments of the present invention are provided to more fully explain the invention to those of ordinary skill in the art. Therefore, the embodiments of the present invention may be modified in various ways, and the scope of the present invention is not limited to the embodiments described below.
[0037] As used herein, the term "epitope" refers to a protein determinant capable of specific binding to an antibody. Epitopes typically consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural characteristics, as well as specific charge characteristics.
[0038] The term "treatment" means any process that may slow, stop, halt, control, arrest, alleviate or improve the symptoms or complications of a disorder or condition disclosed herein, or reverse its progression, but does not necessarily represent complete elimination of all symptoms of the disorder or condition.
[0039] The term "prevention" means the preventive treatment of a disease or disorder, for example, or delaying the onset or progression of a disease or disorder.
[0040] The term "subject" or "subject" refers to a mammal, including, but not limited to, a human, bovine, equine, feline, canine, rodent, or primate. In some embodiments, the subject is a human.
[0041] The term "antibody" is used in its broadest sense and encompasses a variety of antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antigen-binding fragments thereof, as long as they exhibit the desired antigen-binding activity. The term "antibody" includes conventional four-chain antibodies, single-domain antibodies, and antigen-binding fragments thereof.
[0042] The basic four-chain antibody unit is a heterotetrameric glycoprotein composed of two identical light (L) chains and two identical heavy (H) chains. IgM antibodies consist of five of the basic heterotetrameric units along with an additional polypeptide called the J chain, containing ten antigen-binding sites, whereas IgA antibodies contain two to five of the basic four-chain units that can polymerize to form multivalent aggregates in combination with the J chain. For IgG, the four-chain unit is typically about 150,000 daltons. Each L chain is linked to an H chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds, depending on the H chain isotype. Each H and L chain also has regularly spaced interchain disulfide bridges. Each H chain has, at its N-terminus, a variable domain (VH) followed by three constant domains (CH) for each of the α and γ chains, and four CH domains for the μ and ε isotypes. Each L chain has, at its other end, a variable domain (VL) followed by a constant domain at its N-terminus. The VL aligns with the VH, and the CL aligns with the first constant domain (CH1) of the heavy chain. The pairing of the VH and VL together forms a single antigen-binding site. L chains from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequence of their constant domains. Depending on the amino acid sequence of the constant domain (CH) of their heavy chain, immunoglobulins can be assigned to different classes, or isotypes. There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with a heavy chain designated α, δ, ε, γ, and μ, respectively.The γ and α classes are further divided into subclasses based on relatively minor differences in CH sequence and function; for example, humans express the following subclasses: IgG1, IgG2A, IgG2B, IgG3, IgG4, IgA1, and IgA2.
[0043] The term "heavy chain-only antibody" or "HCAb" refers to a functional antibody that contains a heavy chain but lacks the light chain commonly found in four-chain antibodies.
[0044] The term "single-domain antibody," "nanobody," or "sdAb" refers to a single antigen-binding polypeptide having three complementarity determining regions (CDRs). An sdAb alone can bind an antigen without pairing with a corresponding CDR-containing polypeptide. In some cases, single-domain antibodies are engineered from camelid HCAbs, and their heavy chain variable domains are referred to herein as "VHH" (the variable domain of the heavy chain of a heavy chain antibody). A basic VHH has the following structure from N-terminus to C-terminus: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR1 to FR4 refer to framework regions 1 to 4, respectively, and CDR1 to CDR3 refer to complementarity determining regions 1 to 3.
[0045] The "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of the heavy or light chain of the antibody. The variable domains of the heavy and light chains may be referred to as "VH" and "VL," respectively. These domains are generally the most variable portions of the antibody (compared to other antibodies of the same class) and contain the antigen-binding site. Heavy-chain-only antibodies from Camelidae species have a single heavy chain variable region, referred to as "VHH."
[0046] The term "variable" refers to the fact that specific segments of the variable domains differ extensively in sequence among antibodies. The V domain mediates antigen binding and defines the specificity of a particular antibody for its particular antigen. However, variability is not evenly distributed across the entire variable domain. Instead, it is concentrated in three segments, called complementarity determining regions (CDRs) or hypervariable regions (HVRs), in both heavy and light chain variable domains. The more highly conserved portions of the variable domains are called framework regions (FRs). The variable domains of native heavy and light chains each contain four FR regions, which predominantly adopt a beta-sheet configuration, and in some cases form part of a beta-sheet structure, connected by three CDRs that form loop connections. In each chain, the CDRs are held together in close proximity by the FR regions, and the CDRs from the other chain contribute to the formation of the antigen-binding site of the antibody (see Kabat, Elvin A., Sequence of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991)). The constant domains are not directly involved in binding the antibody to the antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular cytotoxicity.
[0047] The term "constant domain" refers to the portion of an immunoglobulin molecule that has a more conserved amino acid sequence than the variable domain, another portion of the immunoglobulin that contains the antigen-binding site. The constant domain contains the CH1, CH2, and CH3 domains (collectively, CH) of the heavy chain and the CHL (or CL) domain of the light chain.
[0048] The terms "full-length antibody," "intact antibody," or "whole antibody" are used interchangeably to refer to an antibody in its substantially intact form, as opposed to an antibody fragment. Specifically, full-length four-chain antibodies include those having heavy and light chains that include an Fc region. Full-length heavy-chain-only antibodies include a heavy chain variable domain (e.g., VHH) and an Fc region.
[0049] The constant domain may be a native sequence constant domain (e.g., a human native sequence constant domain) or an amino acid sequence variant thereof. In some cases, an intact antibody may have more than one effector function.
[0050] An "antibody fragment" or "antigen-binding fragment" comprises a portion of an intact antibody, preferably the antigen-binding and / or variable region of an intact antibody. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; single-chain antibody (scFv) molecules; single-domain antibodies (e.g., VHH), and multispecific antibodies formed from antibody fragments. An "Fv" is the smallest antibody fragment that contains a complete antigen-recognition and -binding site. This fragment consists of a dimer of one heavy chain and one light chain variable region domain in compact, non-covalent association. A "single-chain Fv," also abbreviated "sFv" or "scFv," is an antibody fragment comprising the VH and VL antibody domains linked in a single polypeptide chain. Preferably, the scFv polypeptide further comprises a polypeptide linker between the VH and VL domains that enables the scFv to form the desired structure for antigen binding. "Diabodies" refer to small antibody fragments prepared by constructing sFv fragments with a short linker (about 5-10 residues) between the VH and VL domains to achieve interchain rather than intrachain pairing of the V domains, thereby resulting in a bivalent fragment, i.e., a fragment having two antigen-binding sites. Bispecific diabodies are heterodimers of two "crossed" sFv fragments in which the VH and VL domains of the two antibodies are present on different polypeptide chains.
[0051] The term "humanized antibodies" is used as a subset of "chimeric antibodies".
[0052] A "humanized" form of a non-human (e.g., llama or camelid) antibody is a chimeric antibody that contains minimal sequence derived from a non-human immunoglobulin. In some embodiments, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from a CDR (as defined below) of the recipient are replaced with residues from a CDR of a non-human species (donor antibody) such as mouse, rat, rabbit, camel, llama, alpaca, or non-human primate having the desired specificity, affinity, and / or capacity.
[0053] In some cases, framework ("FR") residues of human immunoglobulins are replaced with corresponding non-human residues. Furthermore, humanized antibodies may include residues not found in either the recipient antibody or the donor antibody. These modifications may be made to further improve antibody performance, such as binding affinity.
[0054] The term "hypervariable region," "HVR," or "HV," as used herein, refers to a region of an antibody variable domain that is hypervariable in sequence and / or forms structurally defined loops. Typically, single-domain antibodies comprise three HVRs (or CDRs): HVR1 (or CDR1), HVR2 (or CDR2), and HVR3 (or CDR3). HVR3 (or CDR3) exhibits the greatest diversity of the three HVRs and is known to play a unique role in conferring fine specificity to antibodies. See, e.g., Hamers-Casterman et al., Nature 363:446-448 (1993); Sheriff et al., Nature Struct. Biol. 3:733-736 (1996).
[0055] The term "complementarity determining region" or "CDR" is used to refer to a hypervariable region as defined by the Kabat system. See Kabat, Elvin A., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991). The Kabat complementarity determining region (CDR) is based on sequence variability and is the most commonly used.
[0056] The term "framework" or "FR" residues refers to variable-domain residues other than HVR residues as defined herein.
[0057] The term “specific” refers to selective recognition of an antigen binding protein (e.g., sdAb) against a particular epitope of an antigen.
[0058] Natural antibodies, for example, are monospecific. As used herein, the term "multispecific" indicates that an antigen binding protein has polyepitopic specificity (i.e., can specifically bind to two, three, or more different epitopes on a single biological molecule or can specifically bind to epitopes on two, three, or more different biological molecules). As used herein, "bispecific" indicates that an antigen binding protein has two different antigen-binding specificities.
[0059] As used herein, the term "monospecific" refers to an antigen binding protein having one or more binding sites each that bind the same epitope of the same antigen.
[0060] The term "a" indicates the presence of a specified number of binding sites in an antigen binding protein. For example, the terms "bivalent," "trivalent," "tetravalent," "pentavalent," and "hexavalent" indicate the presence of two binding sites, three binding sites, four binding sites, five binding sites, and six binding sites in an antigen binding protein.
[0061] "Antibody effector functions" refer to those biological activities attributable to the Fc region of an antibody (either a native sequence Fc region or an amino acid sequence variant Fc region) and vary with antibody isotype. Examples of antibody effector functions include: Clq binding and complement-dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of cell surface receptors (e.g., B cell receptor); and B cell activation. "Complement-dependent cytotoxicity" or "CDC" refers to the lysis of target cells in the presence of complement. Activation of the classical complement pathway is initiated by the binding of the first component (Clq) of the complement system to antibodies (of the appropriate subclass) bound to their cognate antigen. "Antibody-dependent cell-mediated cytotoxicity" or ADCC refers to a form of cytotoxicity in which secreted Ig bound to Fc receptors (FcRs) present on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages) causes these cytotoxic effector cells to specifically bind antigen-bearing target cells and subsequently kill the target cells with cytotoxins.
[0062] The term "Fc region" or "fragment crystallizable region" is used herein to define the C-terminal region of an immunoglobulin heavy chain, including native-sequence Fc regions and variant Fc regions. Suitable native-sequence Fc regions for use in the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4.
[0063] "Binding affinity" generally refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise specified, as used herein, "binding affinity" refers to the intrinsic binding affinity reflecting a 1:1 interaction between members of a binding pair. Binding affinity may be expressed as Kd, Koff, Kon, or Ka. As used herein, the term equilibrium dissociation constant "KD" or "Kd" refers to the dissociation constant of a particular antibody-antigen interaction, describes the concentration of antigen required to occupy one-half of all antibody-binding domains present in solution of an antibody molecule at equilibrium, and is expressed in units of M. Measurements of KD assume that all binding agents are in solution. The dissociation constant (KD or Kd) is used as an indicator of the affinity of an antibody for its antigen. For example, simple analysis is possible using the Scatchard method, which utilizes antibodies labeled with various marker preparations, as well as over-the-counter drug products and assay kits, following the user's manual and experimental operating instructions attached to the kit. KD values derived using these methods are expressed in units of M (Mols).
[0064] "Percent (%) amino acid sequence identity" and "homology" with respect to peptide, polypeptide, or antibody sequences are defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the specific peptide or polypeptide sequence, after sequence alignment and gap introduction, if necessary, and without considering any conservative substitutions as part of the sequence identity, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, or MEGALIGN™ (DNATAR) software. One skilled in the art can determine appropriate parameters for measuring alignment, including any algorithm necessary to achieve maximum alignment over the full length of the sequences to be compared.
[0065] The present invention relates to antibodies or antigen-binding fragments thereof comprising a single domain antibody (sdAb) that specifically binds to SERPIN A12 (hereinafter referred to as "anti-SERPIN A12 sdAb"), such as anti-SERPIN A12 sdAbs, anti-SERPIN A12 heavy chain-only antibodies (HCAbs) (e.g., anti-SERPIN A12 sdAb-Fc fusion proteins in which anti-SERPIN A12 sdAb is fused to a crystalline fragment (Fc fragment) of human immunoglobulin G (IgG)), or other sdAbs, full-length 4-chain antibodies or antigen-binding fragments thereof (e.g., Fab or scFv), and to the preparation and use thereof.
[0066] Accordingly, the present invention provides an antibody or antigen-binding fragment thereof comprising an anti-SERPIN A12 sdAb.
[0067] In the present invention, the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb may be an anti-SERPIN A12 sdAb or an antigen-binding fragment thereof.
[0068] In the present invention, the anti-SERPIN A12 sdAb comprises a CDR1 consisting of an amino acid sequence represented by SEQ ID NO: 2; a CDR2 consisting of an amino acid sequence represented by SEQ ID NO: 3; and a CDR3 consisting of an amino acid sequence represented by SEQ ID NO: 4.
[0069] The above CDR sequences are provided in Table 1 below.
[0070] Sequence CDR1GESLGYYA (SEQ ID NO: 2)CDR2ISSTGGTT (SEQ ID NO: 3)CDR3AAQIRETRGLWEDYDF (SEQ ID NO: 4)
[0071] In the present invention, the anti-SERPIN A12 sdAb may comprise any suitable sequence for the FR region. Specifically, the FR sequence may be an amino acid sequence shown in Table 2 below.
[0072] Sequence FR1QVQLAESGGGLVQSGGSLRLSCTDS (SEQ ID NO: 5) FR2VGWFRQAPGKEREGVSW (SEQ ID NO: 6) FR3DYADSVKDRFTISRDNANDKVYLQMNSLKHEDTGVYYC (SEQ ID NO: 7) FR4WGQGTQVTVSS (SEQ ID NO: 8)
[0073] More specifically, the anti-SERPIN A12 sdAb may comprise the following FR1, FR2, FR3 and FR4: FR1 consisting of an amino acid sequence represented by SEQ ID NO: 5;
[0074] FR2 consisting of an amino acid sequence represented by sequence number 6;
[0075] FR3 consisting of an amino acid sequence represented by sequence number 7; and
[0076] FR4 consisting of the amino acid sequence represented by sequence number 8.
[0077] In the present invention, the anti-SERPIN A12 sdAb may comprise a VHH domain including the FR region.
[0078] Specifically, the anti-SERPIN A12 sdAb may comprise an amino acid sequence represented by SEQ ID NO: 1, or a variant thereof having at least 80% (e.g., at least any of 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity to the amino acid sequence.
[0079] In the present invention, the anti-SERPIN A12 sdAb may be monomeric or multimeric. Furthermore, when multimeric, it may be multispecific and multivalent (e.g., bispecific and bivalent), for example, comprising two or more different anti-SERPIN A12 sdAbs described herein, or monospecific and multivalent (e.g., bivalent), comprising two or more copies of the same anti-SERPIN A12 sdAb. Furthermore, the sdAbs may be fused via a peptide linker. In some embodiments, the peptide linker comprises flexible residues (e.g., glycine and serine) such that adjacent domains are free to move relative to one another. For example, a glycine-serine doublet may be a suitable peptide linker. Furthermore, the peptide linker may be of any suitable length. In some embodiments, the peptide linker is at least about any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100 or more amino acids in length.
[0080] In the present invention, the anti-SERPIN A12 sdAb binds to an epitope of SERPIN A12.
[0081] Additionally, the KD of the binding between the anti-SERPIN A12 sdAb and SERPIN A12 was 10 -6 M to 10 -12 M, 10 -6 M to 10 -11 M, 10 -6 M to 10 -10 M, 10 -6 M to 10 -9 M, or 10 -6 M to 10 -8 It could be M.
[0082] Additionally, the EC of the anti-SERPIN A12 sdAb 50 In FACS analysis, the concentration may be less than 500 nM, and specifically may be 0.1 nM to 500 nM, 0.1 nM to 400 nM, 0.1 nM to 300 nM, 0.1 nM to 200 nM, 0.1 nM to 100 nM, 0.1 to 50 nM, 0.1 to 10 nM, 1 nM to 500 nM, 1 nM to 400 nM, 1 nM to 300 nM, 1 nM to 200 nM, 1 nM to 100 nM, 1 to 50 nM or 1 to 10 nM.
[0083] Single domain antibodies (sdAbs) according to the present invention can include, but are not limited to, heavy chain variable domains from heavy chain-only antibodies (e.g., VHH (the variable domain of the heavy chain of a heavy chain antibody) in Camelidae), light chains derived from conventional four-chain antibodies, binding molecules naturally lacking a single domain (e.g., VH or VL), humanized heavy chain-only antibodies, human single domain antibodies produced by transgenic mice or rats expressing human heavy chain segments, and engineered domains and single domain scaffolds other than those derived from antibodies. sdAbs can be derived from any species including, but not limited to, mouse, rat, human, camel, llama, lamprey, fish, shark, goat, rabbit, and bovine. They can also include naturally occurring sdAb molecules from species other than Camelidae.
[0084] Additionally, sdAbs are derived from naturally occurring single-domain antigen-binding molecules known as light-chain-deficient heavy chain antibodies. Such single-domain molecules are disclosed, for example, in WO 94 / 04678 and Hamers-Casterman, et al., (1993) Nature 363:446-448. The variable domain derived from a heavy chain molecule naturally lacking a light chain is referred to herein as a VHH to distinguish it from the conventional VH of four-chain immunoglobulins. Such VHH molecules can be derived from antibodies produced in Camelidae species, such as camels, llamas, vicuñas, dromedaries, alpacas, and guanacos. Species other than Camelidae can produce heavy chain molecules naturally lacking light chains, and such VHHs are within the scope of the present disclosure.
[0085] Additionally, sdAbs can be recombinant, CDR-grafted, humanized, camelized, de-immunized, and / or produced in vitro (e.g., selected by phage display). In some embodiments, the amino acid sequence of the framework regions can be altered by "camelization" of specific amino acid residues in the framework regions. Camelization refers to the replacement or substitution of one or more amino acid residues in the amino acid sequence of a (naturally occurring) VH domain from a conventional four-chain antibody by one or more of the amino acid residues occurring at the corresponding position(s) in the VHH domain of a heavy chain antibody, and can be performed in a manner known in the art.
[0086] Additionally, the sdAb may be a human sdAb produced by a transgenic mouse or rat expressing a human heavy chain segment.
[0087] For example, see patents US20090307787A1, US8,754,287, US20150289489A1, US20100122358A1, and WO 2004049794.
[0088] Additionally, naturally occurring VHH domains for a particular antigen or target can be obtained from (naive or immune) libraries of Camelidae VHH sequences. Such methods may or may not involve screening such libraries using the antigen or target, or at least portions, fragments, antigenic determinants, or epitopes thereof using one or more screening techniques known per se. Such libraries and techniques are described, for example, in patents WO 99 / 37681, WO 01 / 90190, WO 03 / 025020, and WO 03 / 035694. Alternatively, improved synthetic or semi-synthetic libraries derived from (naive or immune) VHH libraries, such as VHH libraries obtained from (naive or immune) VHH libraries by techniques such as random mutagenesis and / or CDR shuffling, as described, for example, in patent WO 00 / 43507, may be used.
[0089] Additionally, sdAbs can be generated from conventional four-chain antibodies. See, e.g., Ward et al., Nature 1989 Oct. 12; 341 (6242): 544-6, Holt et al., Trends Biotechnol., 2003, 21(11):484-490; Patents WO 06 / 030220; and WO06 / 003388.
[0090] Additionally, the sdAb according to the present invention may be a chimeric antibody. Particular chimeric antibodies are described, for example, in U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984). In some embodiments, a chimeric antibody may comprise a non-human variable region (e.g., a variable region derived from a camelid species, such as a llama) and a human constant region. Additionally, a chimeric antibody may be humanized. Typically, a non-human antibody is humanized to reduce immunogenicity toward humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. The humanized antibody will optionally also comprise at least a portion of a human constant region. In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), for example, to restore or improve antibody specificity or affinity.
[0091] In the present invention, the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb may be an anti-SERPIN A12 HCAb or an antigen-binding fragment thereof.
[0092] Specifically, the anti-SERPIN A12 HCAb is an anti-SERPIN A12 sdAb described herein fused to one or more CH2 and / or CH3 domains, e.g., an Fc fragment.
[0093] The CH2 and / or CH3 domains are derived from an immunoglobulin. The immunoglobulin may be IgA, IgD, IgE, IgG, or IgM, and specifically may be IgG. In some embodiments, the anti-SERPIN A12 HCAb may comprise an Fc fragment of an IgG, such as IgG1, IgG2, IgG3, or IgG4, wherein the Fc fragment may be a human Fc, such as human IgG1 (hIgG1) Fc, hIgG2 Fc, hIgG3 Fc, or hIgG4 Fc.
[0094] The anti-SERPIN A12 HCAb may be monomeric or multimeric. Furthermore, if multimeric, it may be multispecific and multivalent (e.g., bispecific and bivalent), for example, comprising two or more different anti-SERPIN A12 sdAbs described herein, or monospecific and multivalent (e.g., bivalent), for example, comprising two or more copies of the same anti-SERPIN A12 sdAb.
[0095] In the present invention, the anti-SERPIN A12 sdAb and the CH2 and / or CH3 domains, specifically the Fc fragment, can be fused via a peptide linker. The length, degree of flexibility, and / or other characteristics of the peptide linker may have some influence on the properties, including but not limited to affinity, specificity, or binding ability to one or more specific antigens or epitopes. For example, a longer peptide linker may be selected to ensure that two adjacent domains do not sterically hinder each other. In some embodiments, the peptide linker includes flexible residues (e.g., glycine and serine) to allow the adjacent domains to move freely relative to each other. For example, a glycine-serine doublet may be a suitable peptide linker. Furthermore, the peptide linker may be of any suitable length. In some embodiments, the peptide linker is at least about any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 50, 75, 100 or more amino acids in length.
[0096] Additionally, the peptide linker may have a naturally occurring sequence or a non-naturally occurring sequence. For example, a sequence derived from the hinge region of a heavy-chain-only antibody may be used as a linker. See, e.g., patent WO 1996 / 34103.
[0097] In some embodiments, the peptide linker can be a hIgG1 hinge, a hIgG2 hinge, a hIgG3 hinge, a hIgG4 hinge, or a variant thereof.
[0098] In the present invention, the antibody comprising the anti-SERPIN A12 sdAb or an antigen-binding fragment thereof may be a multispecific antigen binding protein (MABP) in which the anti-SERPIN A12 sdAb is fused to another sdAb, a full-length 4-chain antibody or an antigen-binding fragment thereof (e.g., a bispecific antigen binding protein (BABP) in which the anti-SERPIN A12 sdAb is fused (hereinafter referred to as anti-SERPIN A12 BABP)) or an antigen-binding fragment thereof.
[0099] The anti-SERPIN A12 BABP comprises (a) a first antigen binding moiety comprising an anti-SERPIN A12 sdAb as described herein; and (b) a second antigen binding moiety that specifically binds to a second epitope.
[0100] The second epitope may be an antigen other than SERPIN A12, or a second epitope in SERPIN A12.
[0101] The second antigen-binding moiety can be a full-length antibody, a Fab, a Fab', a (Fab')2, an Fv, a single-chain Fv (scFv), a scFv-scFv, a minibody, a diabody, or a second sdAb. Additionally, the second antigen-binding moiety can comprise a heavy chain comprising a VH and a light chain comprising a VL. In some embodiments, the first antigen-binding moiety can be fused to the second antigen-binding moiety at the N-terminus of the heavy chain, the N-terminus of the light chain, the N-terminus of the Fc region, the C-terminus of the heavy chain, or the C-terminus of the light chain. In some embodiments, the second antigen-binding moiety can comprise a Fab or a scFv. In some embodiments, the first antigen-binding moiety can be fused to the second antigen-binding moiety at the C-terminus of the Fab or scFv. In some embodiments, the second antigen-binding moiety can comprise a full-length 4-chain antibody. In some embodiments, the first antigen-binding moiety can be fused to a second antigen-binding moiety via a peptide linker. In some embodiments, the second antigen-binding moiety can comprise an Fc region, such as an IgG1 Fc, an IgG2 Fc, an IgG3 Fc, or an IgG4 Fc.
[0102] The anti-SERPIN A12 MABP comprises at least two antigen-binding moieties that specifically bind at least two different epitopes. Some of the at least two antigen-binding moieties may be identical, so long as the MABP has binding sites for two different epitopes. Furthermore, the anti-SERPIN A12 MABP may comprise any one of one, two, three, four, five, six, seven, eight, or more different antigen-binding moieties, each comprising an anti-SERPIN A12 sdAb described herein.
[0103] Additionally, the anti-SERPIN A12 MABP can have any suitable number of valencies and any suitable number of specificities for the first epitope and / or the second epitope of SERPIN A12. In some embodiments, the anti-SERPIN A12 MABP can be divalent, trivalent, tetravalent, pentavalent, hexavalent, or higher valency for SERPIN A12. In some embodiments, the MABP can be trispecific, or tetraspecific.
[0104] Techniques for producing multispecific antibodies according to the present invention include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (e.g., Milstein and Cuello, Nature 305: 537 (1983)); WO 93 / 08829; Traunecker et al., EMBO J. 10: 3655 (1991)), and "knob-in-hole" engineering (e.g., patent US5731168). Multispecific antibodies can also be produced by engineering electrostatic steering effects for producing antibody Fc-heterodimeric molecules (WO2009 / 089004A1); cross-linking of two or more antibodies or fragments (e.g., patent US4676980, and Brennan et al., Science, 229: 81 (1985)); The use of leucine zippers to produce bispecific antibodies (e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); the use of "diabody" technology for the production of bispecific antibody fragments (e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and the use of single-chain Fv (sFv) dimers (e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and the production of trispecific antibodies, as described, for example, in Tutt et al., J. Immunol. 147: 60 (1991); and the creation of polypeptides comprising tandem single-domain antibodies (e.g., patent US20110028695; and Conrath et al., J. Biol. Chem., 2001; 276(10):7346-50).
[0105] In the present invention, the antibody or antigen-binding fragment thereof including the anti-SERPIN A12 sdAb comprises an amino acid sequence variant.
[0106] Amino acid sequence variants of an antibody can be prepared by introducing appropriate modifications into the nucleic acid sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, deletions, insertions, and / or substitutions of residues within the amino acid sequence of the antibody. Any combination of deletions, insertions, and substitutions can be made to achieve a final construct, provided that the final construct retains the desired characteristics, e.g., antigen-binding. In some embodiments, substitutions, insertions, or deletions can occur within one or more hypervariable regions (HVRs), as long as such alterations do not substantially reduce the antibody's ability to bind antigen. For example, conservative alterations that do not substantially reduce binding affinity can be made in HVRs. Such alterations can be within HVR "hot spots" or outside of the CDRs.
[0107] Additionally, the amino acid substitution can be at least one (e.g., any one, two, three, four, five, six, seven, eight, nine, or ten) amino acid substitution. Additionally, the at least one amino acid substitution can be a conservative substitution, or a substitution with a non-genetically encoded amino acid or a synthetic amino acid. In some embodiments, the amino acid substitution can be in a CDR region and can comprise at least one (e.g., any one, two, three, or four) amino acid substitution in CDR1, CDR2, and / or CDR3. In some embodiments, the amino acid substitution can be in a FR region and can comprise at least one (e.g., any one, two, three, four, five, or six) amino acid substitution in FR1, FR2, FR3, and / or FR4.
[0108] Additionally, the amino acid sequence insertions include amino- and / or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing more than 100 residues, as well as intrasequence insertions of single or multiple amino acid residues. An example of a terminal insertion includes an antibody having an N-terminal methionyl residue. Other insertional variants of the antibody molecule may include fusions to the N- or C-terminus of the antibody to a polypeptide or an enzyme (e.g., in the case of ADEPT) that increases the serum half-life of the antibody.
[0109] Additionally, one or more amino acid modifications can be introduced into the Fc region of an antibody or antigen-binding fragment thereof (e.g., an anti-SERPIN A12 HCAb, or an anti-SERPIN A12 MABP), including an anti-SERPIN A12 sdAb provided herein, thereby generating an Fc region variant. The Fc region variant can comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3, or IgG4 Fc) comprising an amino acid modification (e.g., a substitution) at one or more amino acid positions.
[0110] In the present invention, the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb may be linked to, fused to, conjugated to (e.g., covalently or non-covalently) or otherwise associated with a diagnostic moiety or a biocompatibility modifier. For example, a peptide or polypeptide (e.g., a biotoxin, a biomarker, a purification tag, etc.), a protein, a polymer, a nucleic acid molecule, a small molecule, a mimetic, a synthetic drug, an inorganic molecule, an organic molecule, or a radioisotope may be conjugated or associated therewith.
[0111] Additionally, the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb may be conjugated or associated with a diagnostic or detectable agent, marker or reporter, which may be a biological molecule (e.g., a peptide or nucleotide), a small molecule, a fluorophore, or a radioisotope. The labeled modulator may be useful for monitoring the development or progression of a disease associated with SERPIN A12, such as cancer, or for determining the efficacy of a particular therapy comprising the antibodies disclosed herein (i.e., theragnosis), or as part of a clinical trial procedure to determine a future course of treatment. Such markers or reporters may also be useful for purifying the antibodies disclosed herein.
[0112] In addition, the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb may be conjugated to an immunomodulator, a cytokine, a cytotoxic agent, a chemotherapeutic agent, a diagnostic agent, an antiviral agent, an antimicrobial agent, or a drug. Accordingly, the present invention provides an antibody conjugate comprising an antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb according to the present invention conjugated to an immunomodulator, a cytokine, a cytotoxic agent, a chemotherapeutic agent, a diagnostic agent, an antiviral agent, an antimicrobial agent, or a drug.
[0113] The present invention also provides a nucleic acid molecule encoding an antibody or antigen-binding fragment thereof comprising an anti-SERPIN A12 sdAb disclosed herein, an expression vector comprising the nucleic acid molecule, and a host cell transformed with the expression vector.
[0114] The nucleic acid sequence is not limited thereto, but may be, for example, SEQ ID NO: 9. However, a nucleic acid sequence capable of producing a single domain antibody including the CDR sequence desired in the present invention is included within the scope of the present invention.
[0115] The present invention also provides a method for producing an antibody or an antigen-binding fragment thereof, comprising the steps of (a) culturing the host cell under conditions that allow the antibody to be expressed; and (b) recovering the expressed antibody or antigen-binding fragment thereof.
[0116] In the present invention, DNA encoding an antibody or antigen-binding fragment thereof, including an anti-SERPIN A12 sdAb disclosed herein, can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes capable of specifically binding to genes encoding antibody heavy and light chains). Isolated and subcloned hybridoma cells (or phage or yeast-derived colonies) can serve as a preferred source of such DNA. More particularly, the isolated DNA (which may be modified) can be used to clone constant and variable region sequences for the production of antibodies.
[0117] One exemplary method involves extracting RNA from selected cells, converting it to cDNA, and amplifying it by PCR using antibody-specific primers. Suitable primers are well known in the art and readily available from many commercial sources, as exemplified herein. To express a recombinant human or non-human antibody isolated by screening a combinatorial library, the DNA encoding the antibody is cloned into a recombinant expression vector and introduced into a host cell, including mammalian cells, insect cells, plant cells, yeast, and bacteria. In some embodiments, a modulator is introduced into and expressed by monkey COS cells, NS0 cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce the desired construct.
[0118] In the present invention, the nucleic acid molecule is present within a vector, where appropriate, together with a promoter that controls expression of the nucleic acid.
[0119] The term "vector" is used in its most general sense and includes any intermediate vehicle for nucleic acids, which allows the nucleic acid to be introduced into, for example, a prokaryotic and / or eukaryotic cell and, where appropriate, integrated into the genome. Vectors of this type are preferably replicated and / or expressed within the cell. The vector may comprise a plasmid, phagemid, bacteriophage, or viral genome. The plasmid generally refers to an extrachromosomal genetic material construct capable of replicating independently of chromosomal DNA, typically a circular DNA duplex.
[0120] Expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals can be constructed using methods well known to those skilled in the art. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.
[0121] In the present invention, the host cell or recombinant host cell refers to a cell into which an expression vector has been introduced. The terms "recombinant host cell" and "host cell" refer not only to a specific target cell but also to the progeny of such a cell. Since certain modifications may occur in subsequent generations due to mutation or environmental influences, such progeny may not be substantially identical to the parent cell, but are still included within the scope of the term "host cell" as used herein. Such cells may contain a vector as described above.
[0122] Additionally, substantial quantities of the antibodies disclosed herein can be produced using molecular biology techniques recognized in the art and current protein expression methodologies. More specifically, nucleic acid molecules encoding such antibodies can be incorporated into well-known and commercially available protein production systems, including various types of host cells, to provide preclinical, clinical, or commercial quantities of the desired pharmaceutical product. In some embodiments, nucleic acid molecules encoding the antibodies are engineered into vectors or expression vectors that provide for efficient integration into selected host cells and subsequent high levels of antibody expression.
[0123] Preferably, nucleic acid molecules encoding the antibodies disclosed herein and vectors comprising these nucleic acid molecules can be used to transfect suitable mammalian, plant, bacterial, or yeast host cells, although prokaryotic systems may also be used. Transfection can be accomplished by any known method for introducing polynucleotides into host cells. Methods for introducing heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene-mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of DNA into the nucleus. Nucleic acid molecules can also be introduced into mammalian cells via viral vectors. Methods for transforming mammalian cells are well known in the art. Methods for transforming plant cells are also well known in the art and include, for example, Agrobacterium-mediated transformation, biolistic transformation, direct injection, electroporation, and viral transformation. Methods for transforming bacterial and yeast cells are also well known in the art.
[0124] Many commercially available host-expression vector systems can be used to express the antibodies disclosed herein. Such host-expression systems not only represent vehicles in which a coding sequence of interest can be expressed and subsequently purified, but also represent cells capable of in situ expressing a molecule of the invention when transformed or transfected with the appropriate nucleotide coding sequence. Such systems include microorganisms, such as bacteria (e.g., E. coli, B. subtilis, Streptomyces), transformed with a recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vector containing a regulator coding sequence; yeast (e.g., Saccharomyces, Pichia) transfected with a recombinant yeast expression vector containing a regulator coding sequence; insect cell systems infected with a recombinant virus expression vector (e.g., baculovirus) containing a regulator coding sequence; Plant cell systems (e.g., Nicotiana, Arabidopsis, duckweed, maize, wheat, potato, etc.) infected with a recombinant virus expression vector (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transfected with a recombinant plasmid expression vector containing a regulator coding sequence (e.g., Ti plasmid); or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring a recombinant expression construct containing a promoter derived from the genome of a mammalian cell (e.g., metallothionein promoter) or derived from a mammalian virus (e.g., adenovirus late promoter; vaccinia virus 7.5K promoter).
[0125] If the antibodies disclosed herein are produced by recombinant expression or any of the other techniques disclosed herein, they may be purified by any method known in the art for purifying immunoglobulins, or more generally by any other standard technique for purifying proteins.
[0126] In addition, the present invention provides a pharmaceutical composition for preventing or treating bone disease, comprising as an active ingredient an antibody or an antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb disclosed herein, or an antibody conjugate comprising the antibody or an antigen-binding fragment thereof.
[0127] The present invention also provides a method for preventing or treating bone disease, comprising administering to a subject a pharmaceutical composition comprising a pharmaceutically effective amount of an antibody or antigen-binding fragment thereof comprising an anti-SERPIN A12 sdAb disclosed herein, or an antibody conjugate comprising the antibody or antigen-binding fragment thereof.
[0128] The present invention also provides the use of an antibody or antigen-binding fragment thereof, or an antibody conjugate comprising the antibody or antigen-binding fragment thereof, comprising an anti-SERPIN A12 sdAb disclosed herein for use in the prevention or treatment of bone disease.
[0129] In the present invention, the bone disease may be at least one selected from the group consisting of osteoporosis, periodontal disease, rheumatoid arthritis, multiple myeloma, degenerative arthritis, inflammatory alveolar bone resorption disease, and inflammatory bone resorption disease.
[0130] In the present invention, the content of the antibody or antigen-binding fragment thereof including the anti-SERPIN A12 sdAb, or the antibody conjugate including the antibody or antigen-binding fragment thereof, is the same as described above, so the specific description is based on the above content, and only the unique configuration of the pharmaceutical composition and use is described below.
[0131] A pharmaceutical composition according to the present invention may comprise an antibody or antigen-binding fragment thereof comprising one or more (e.g., two or three) anti-SERPIN A12 sdAbs described herein, or a drug conjugate comprising said antibody or antigen-binding fragment thereof.
[0132] By administering the pharmaceutical composition according to the present invention to a subject, specifically a patient with a bone disease, bone disease can be prevented or treated.
[0133] Furthermore, the pharmaceutical compositions according to the present invention can be formulated as desired using techniques recognized in the relevant art, depending on the form of the antibody described herein, the intended mode of delivery, and numerous other variables. Furthermore, they can be formulated to contain suitable pharmaceutically acceptable carriers, including excipients and auxiliaries, which are relatively inert substances well known in the relevant art and which facilitate administration or aid in processing the active compound into a pharmaceutically optimized formulation for delivery. For example, various pharmaceutically acceptable carriers, including vehicles, auxiliaries, and diluents, are readily available from numerous commercial sources. Furthermore, classes of pharmaceutically acceptable auxiliary substances, such as pH adjusters and buffers, tonicity adjusters, stabilizers, wetting agents, and the like, are also available. Specific, non-limiting exemplary carriers include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
[0134] Furthermore, the pharmaceutical composition according to the present invention may be formulated for enteral, parenteral, or topical administration. In fact, all three types of formulations can be used simultaneously to achieve systemic administration of the active ingredient. Excipients and formulations for parenteral and non-parenteral drug delivery are well known in the art. Formulations suitable for parenteral administration include aqueous solutions of the active compound in water-soluble form, such as water-soluble salts. Additionally, suspensions of suitable active compounds in oily injection suspensions may be administered. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, and / or dextran. Optionally, the suspensions may also contain stabilizers. Liposomes can also be used to encapsulate agents for delivery into cells.
[0135] Formulations suitable for enteral administration include hard or soft gelatin capsules, pills, tablets including coated tablets, elixirs, suspensions, syrups or inhalants and their controlled release forms.
[0136] In general, the antibodies disclosed herein can be administered in vivo to a subject in need thereof by various routes, including but not limited to, orally, intravenously, intraarterially, subcutaneously, parenterally, intranasally, intramuscularly, intracardiacly, intracerebroventricularly, intratracheally, buccally, rectally, intraperitoneally, intradermally, topically, transdermally, and intrathecally, or otherwise by implantation or inhalation. The appropriate formulation and route of administration can be selected depending on the intended use and therapeutic regimen.
[0137] The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount for the treatment or prevention of cancer. The pharmaceutically effective amount refers to the amount of the antibody or pharmaceutical composition comprising the antibody that will elicit a biological or medical response in a subject, as sought by a physician or other clinician. Furthermore, multiple doses of the antibody or pharmaceutical composition comprising the antibody may be administered at a specific frequency to achieve a therapeutic dose having a preventive and / or therapeutic effect.
[0138] The pharmaceutically effective amount typically depends on the body weight of the subject to be treated, his physical condition, the extent of the condition to be treated, and the age of the subject to be treated. Generally, the antibodies disclosed herein can be administered in an amount ranging from about 10 ng / kg body weight to about 100 mg / kg body weight, from about 50 μg / kg body weight to about 5 mg / kg body weight, from about 100 μg / kg body weight to about 10 mg / kg body weight, from about 100 μg / kg body weight to about 20 mg / kg body weight, or from 0.5 mg / kg body weight to about 20 mg / kg body weight per dose, but is not limited thereto. Furthermore, the antibodies can be administered in a dose of, but is not limited to, at least about 100 μg / kg body weight, at least about 250 μg / kg body weight, at least about 750 μg / kg body weight, at least about 3 mg / kg body weight, at least about 5 mg / kg body weight, or at least about 10 mg / kg body weight.
[0139] In addition, the pharmaceutical composition according to the present invention can be administered in a dosage of about 100 mg to about 10,000 mg, a dosage of about 200 mg to about 9,000 mg, a dosage of about 300 mg to about 8,000 mg, a dosage of about 400 mg to 7,000 mg, or a dosage of 500 mg to 5,000 mg, but is not limited thereto.
[0140] The pharmaceutical composition according to the present invention is typically administered to a patient multiple times. Exemplary treatment regimens involve administration once every two weeks, once a month, or once every three to six months. For example, a patient may receive the antibody (e.g., as an intravenous formulation) in cycles of four weeks, for example, once every 28 days. The frequency of administration may be adjusted based on the pharmacokinetic profile of the antibody in the patient. For example, the half-life of the antibody may require a two-week dosing frequency. In some methods, two or more antibodies with different binding specificities may be administered simultaneously, in which case the dosage of each antibody administered falls within the ranges provided.
[0141] Dosage and frequency vary depending on the half-life of the antibody in the patient. Generally, human antibodies have the longest half-life, followed by humanized antibodies, chimeric antibodies, and non-human antibodies. Dosage and frequency may vary depending on whether the treatment is prophylactic or therapeutic.
[0142] The duration of treatment depends on the disease being treated, the patient's age and condition, the stage and type of the patient's disease, and how the patient responds to treatment. The clinician will closely monitor the effectiveness of the therapy and may make any adjustments as needed. When agents are used in combination, two or more therapeutic agents may be administered simultaneously or sequentially in any order. That is, the antibodies disclosed herein may be administered prior to, concurrently with, or subsequent to the administration of the second therapeutic agent.
[0143] In addition, the present invention
[0144] (i) contacting a sample with an antibody or antigen-binding fragment thereof comprising an anti-SERPIN A12 sdAb disclosed in the present invention; and
[0145] (ii) a step of detecting the formation of a complex between the antibody or antigen-binding fragment thereof and SERPIN A12 or determining the amount of the complex,
[0146] A method for detecting SERPIN A12 or determining the amount of SERPIN A12 in a sample is provided.
[0147] In the present invention, the content of the antibody or antigen-binding fragment thereof comprising the anti-SERPIN A12 sdAb, or the antibody conjugate comprising the antibody or antigen-binding fragment thereof, is the same as described above, and therefore, the specific description is based on the above content.
[0148] In the present invention, the sample may be a sample containing a cell sample.
[0149] The antibody or antigen-binding fragment of the present invention can be used to detect SERPIN A12 or SERPIN A12-expressing cells or determine the amount of SERPIN A12 or SERPIN A12-expressing cells. By detecting or determining the amount of a complex between SERPIN A12 and the antibody or antigen-binding fragment of the present invention, SERPIN A12 or SERPIN A12-expressing cells are detected or the amount of SERPIN A12 or SERPIN A12-expressing cells is determined.
[0150] The formation of a complex indicates the presence of SERPIN A12 or SERPIN A12-expressing cells. Detection or determination of such amounts can be accomplished by a variety of methods, including but not limited to immunodetection using an antibody or antigen-binding fragment of the present invention. Methods utilizing antibodies to detect peptides or proteins are well known and include ELISA, competitive binding assays, and similar methods. Typically, such assays utilize an antibody or antibody fragment that specifically binds to a target peptide or protein, which is then conjugated directly or indirectly to a label providing detection, such as an indicator enzyme, radiolabel, fluorophore, or paramagnetic particle. The methods of the present invention enable quantitative and / or qualitative evaluations, such as absolute and / or relative evaluations, of SERPIN A12 levels or the levels of SERPIN A12-expressing cells.
[0151] The present invention will be described in more detail below through examples. However, these examples are intended to exemplify the present invention and the scope of the present invention is not limited to these examples.
[0152] Example 1. Immunization and blood collection
[0153] Human SerpinA12 protein as an immune antigen was mixed with an immune adjuvant (GERBU) and immunized three times in one alpaca via intramuscular injection. Immunization was performed three times, and 10 ml of blood was collected from each alpaca on the 7th day after the final immunization, and the immune response was analyzed by ELISA. Antibody production was tested by dispensing the immune antigen at a concentration of 1 μg / ml using coating buffer into a 96-well microplate and coating it overnight at 4°C. The 96-well microplate was washed three times with PBST and blocked with 5% skim milk for 2 hours at room temperature to inhibit nonspecific binding. After washing three times with PBST, serum samples collected before immunization (day 0), 14 days (day 14), 28 days (day 28), and 35 days (day 35) after immunization were processed at serial dilutions. Afterwards, the 96-well microplate was washed five times with PBST, and then reacted with goat anti-Llama IgG HRP antibody at room temperature for 1 hour, and the presence of antibody bound to the immune antigen was confirmed by TMB reaction.
[0154] Example 2. Library production and evaluation
[0155] A library was constructed by amplifying a gene encoding a single-domain antibody that binds to an immune antigen. For library construction, peripheral blood mononuclear cells (PBMCs) were isolated from blood using Ficoll. A gene fragment encoding a single-domain antibody was amplified from total RNA extracted from the isolated PBMCs using specific primers and cloned into the pComb3x vector. The size of the constructed immune library was 2.2X10 8 It was.
[0156] Example 3. Bio-panning
[0157] To select single-domain antibodies specific for an immune antigen, 5 ug / ml of SerpinA12 protein was dispensed into a microplate and coated overnight at 4°C. The library to be used in the experiment to select single-domain antibodies (the library of <Example 2> above) was dispensed into a 96-well microplate and incubated at room temperature for 30 minutes. The library was then transferred to a new well and incubated at room temperature for 30 minutes. This process was repeated four times to reduce the nonspecific binding rate of the library. The library was transferred to a 1.7 ml tube and stored at 4°C until use.
[0158] The microplate coated with SerpinA12 protein was washed five times with PBST, then blocked with 5% skim milk for 2 hours at room temperature. After washing five times with PBST, the library with reduced nonspecific binding rate was incubated with binding solution (2.5% skim milk, 0.5% tween-20) at 5 x 10 per well. 12 The virions were divided into virions and reacted at room temperature for 30 minutes. Afterwards, they were washed 10 times with a washing solution (0.5% tween-20) and then washed 3 times with PBST. The phage against the single-domain antibody that specifically binds to the SerpinA12 protein was selectively eluted by adding 20 ug / ml SerpinA12 protein and incubating at room temperature and 500 rpm for 30 minutes. The eluted phage was infected with XL1-blue E. coli in the logarithmic growth phase and then plated on 2XYT agar plates. The panning for second selection was repeated under the same conditions. The single phage clones generated on the agar plates were each amplified and screened using ELISA.
[0159] Example 4. Phage screening
[0160] In order to confirm the binding of the poly phage and the immune antigen at each step amplified through the Bayer panning of Example 3 above, SerpinA12 protein was dispensed at a concentration of 1 ug / ml in a 96-well microplate and coated overnight at 4°C. Afterwards, the plate was washed three times with PBST, and 5% skim milk was added to block for 2 hours at room temperature. Afterwards, the plate was washed three times with PBST, and the poly phage at each step was added at 1 X 10 per well. 13 The 96-well plate was treated with virions and reacted at room temperature for 1 hour. The 96-well plate was washed three times with PBST, treated with anti-M13 g8p antibody HRP (1:5,000, antibody design laboratories), and reacted at room temperature for 1 hour. After washing three times with PBST, TMB substrate (Biolegend) was added and reacted at room temperature for 10 minutes. The reaction was stopped using sulfuric acid, and the absorbance was measured at 450 nm.
[0161] Monophages were isolated from polyphages with increased selective binding to SerpinA12 protein, and candidates that specifically bind to serpinA12 protein were screened using the same method as in Example 4.
[0162] Example 5. Nanobody purification using a Protein G column
[0163] After performing base sequence analysis using the four candidate monophages selected in Example 4 above, one monophage was finally selected. The base sequence of the one finally selected monophage was cloned into the TGEX-Fc expression vector. For the expression of single-domain antibodies, Expi-CHO cells with a viability of 95-99% were counted and 7X10 6The cells were added to 25 ml of Expi-CHO expression medium (Gibco) according to the cell number and cultured overnight at 125 rpm in a 37℃ shaking incubator maintained at 8% CO2. Afterwards, 20 ug of plasmid DNA and 1 ml of OptiPROTM medium were added to a mixture of 80 ul of ExpiFectamineTM CHO reagent (Gibco, 10033021) and 920 ul of OptiPROTM medium, reacted at room temperature for 5 minutes, and then added to the cultured cells. The cells were cultured for 20 hours at 125 rpm in a shaking incubator maintained at 8% CO2. Afterwards, 150 ul of ExpiFectamine CHO enhancer and 6 ml of ExpiCHO Feed were added and cultured for 5 days at 125 rpm in a 32℃ shaking incubator maintained at 5% CO2. Cultured cells were centrifuged at 4,000 rpm for 30 minutes at 4°C, and the supernatant was filtered using a 0.2 μm syringe filter. The supernatant was then loaded onto a HiTrap Protein G HP column, washed with PBS, and single-domain antibodies were separated from the column using IgG elution buffer (Thremo). The eluted sample was neutralized with 1 M Tris-HCl (pH 9.0) and stored at 4°C until use.
[0164] The full-length sequence of the purified nanobody is shown in SEQ ID NO: 1, and the FR and CDR regions are summarized in Tables 1 and 2, respectively.
[0165] Example 6. Evaluation of candidate Serpin A 12 substance
[0166] To confirm the binding of the purified single-domain antibody in <Example 5> to the SerpinA12 protein, the SerpinA12 protein was dispensed at a concentration of 1 ug / ml into a 96-well microplate and coated overnight at 4°C. The plate was then washed three times with PBST and blocked with 2% skim milk for 2 hours at room temperature. The plate was then washed three times with PBST, and the purified single-domain antibody was treated at various concentrations and reacted for 1 hour at room temperature. The plate was washed three times with PBST, treated with anti-human IgG HRP (Jackson Immunoresearch), and reacted for 1 hour at room temperature. After washing three times with PBST, TMB substrate (Biolegend) was added, and the plate was reacted for 10 minutes at room temperature. The reaction was then stopped using sulfuric acid, and the absorbance was measured at 450 nm.
[0167] As a result, as shown in Fig. 1, it was confirmed that the selected single domain antibody binds to the SerpinA12 protein.
[0168] The affinity constant (KD) of the single domain antibody of the above <Example 5> and the SerpinA12 antigen was measured using an Octet RED 96e (ForteBio) device.
[0169] Specifically, anti-human Fc-coated biosensor tips (Fortebio) were saturated to 1.5 nm in a 96-well microplate dispensed with 5 ug / ml of single-domain antibodies. The SerpinA12 antigen was diluted two-fold using 1X kinetic buffer (Fortebio) to a concentration of 3.125 to 100.000 nM, and the reaction was performed at 30°C and 100 rpm with shaking. The binding and dissociation reactions of the samples were analyzed for 200 and 400 s, respectively. The resulting data were analyzed using the 1:1 interaction model (global fitting) method. As a result, as shown in Figure 2, the selected single-domain antibody was confirmed to have an antigen affinity of 0.14 nM for the SerpinA12 protein.
[0170] Example 7. Confirmation of efficacy in treating degenerative arthritis
[0171] Degenerative arthritis was induced by DMM (Destabilization of the Medial Meniscus). Specifically, when degenerative arthritis was induced in mice after DMM surgery, subchondrial bone thickness (SBP) increased from 4 weeks, and joint damage accelerated from 6 weeks.
[0172] Considering the induction and symptoms of degenerative arthritis, the therapeutic efficacy was confirmed by directly injecting the nanobody manufactured through Example 6 into the joint cavity starting 4 weeks after DMM surgery.
[0173] More specifically, the Serpina12 Nanobody identified in Example 6 was injected intra-articularly every week starting from 4 weeks after inducing degenerative arthritis through DMM surgery.
[0174] In the first experiment, the nanobody of Example 6 was administered at 10 μg / μl every week from 4 to 9 weeks after DMM surgery, and its therapeutic efficacy was confirmed through Safranin-O staining and OARSI grade.
[0175] The above experimental schedule and results are shown in Fig. 3.
[0176] As a result, it was confirmed through Safranin-O staining and OARSI grade that degenerative arthritis induced and joint damage was treated by administration of the nanobody according to the present invention.
[0177] After experiment 1, a second experiment was performed while adjusting the dosage, and the nanobody of Example 6 was administered at 5 or 25 μg / μl every week from week 4 to week 9 after DMM surgery, and its therapeutic efficacy was confirmed through Safranin-O staining and OARSI grade.
[0178] The above experimental schedule and results are shown in Fig. 4.
[0179] Mouse knee joints were dissected, fixed in 4% paraformaldehyde, decalcified in 0.5 M EDTA for 2 weeks, and embedded in paraffin. Paraffin blocks were sectioned serially (5 μm thick), and sections were deparaffinized in xylene, rehydrated through graded ethanol solutions, and stained with Safranin-O. Cartilage destruction was scored according to the OARSI grading system (0–6). OARSI scores were expressed as the average maximum score for each mouse, and a representative Safranin-O staining image was selected from the most advanced lesion in each image series section.
[0180] It was confirmed through Safranin-O staining and OARSI grade that the nanobody administration according to the present invention was effective in treating joint damage caused by induced degenerative arthritis. Specifically, in animals with OARSI grades of 5 to 6 and with degenerative arthritis induced by DMM, nanobody administration reduced degenerative arthritis by 26% and 48%, respectively.
[0181] In particular, as shown in Fig. 5, histological analysis also confirmed that the joint breakdown exhibited a characteristic of being alleviated.
[0182] From the above description, those skilled in the art will understand that the present invention can be implemented in other specific forms without altering the technical spirit or essential characteristics of the present invention. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as encompassing all changes or modifications derived from the meaning and scope of the following claims and their equivalent concepts, rather than the detailed description above.
[0183] The single domain antibody that specifically binds to SERPIN A12 according to the present invention has high affinity for Serpin A12 through the high affinity of the single domain antibody for Serpin A12, and exhibits effects of recovering inflammation and improving bone function in bone diseases, and therefore can be used as an effective ingredient of a composition for preventing or treating bone diseases.
Claims
1. An antibody or antigen-binding fragment thereof comprising a single domain antibody (sdAb) that specifically binds to SERPIN A12, An antibody or antigen-binding fragment thereof, wherein the sdAb comprises a CDR1 comprising an amino acid sequence represented by SEQ ID NO: 2; a CDR2 comprising an amino acid sequence represented by SEQ ID NO: 3; and a CDR3 comprising an amino acid sequence represented by SEQ ID NO:
4.
2. In the first paragraph, the sdAb is an antibody or antigen-binding fragment thereof comprising the following VHH domain: FR1 consisting of an amino acid sequence represented by sequence number 5; FR2 consisting of an amino acid sequence represented by sequence number 6; FR3 consisting of an amino acid sequence represented by sequence number 7; and FR4 consisting of the amino acid sequence represented by sequence number 8.
3. In the first paragraph, the sdAb is an antibody or antigen-binding fragment thereof consisting of an amino acid sequence represented by sequence number 1.
4. An antibody or antigen-binding fragment thereof comprising at least one amino acid substitution in the first paragraph.
5. An antibody or antigen-binding fragment thereof, wherein at least one amino acid substitution in paragraph 4 is a conservative substitution.
6. An antibody or antigen-binding fragment thereof, wherein the sdAb is a heavy chain-only antibody (HCAb) fused to an Fc fragment in the first paragraph.
7. A nucleic acid molecule encoding an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6.
8. An expression vector comprising the nucleic acid molecule of paragraph 7.
9. A host cell transformed with the expression vector of paragraph 8.
10. A composition for preventing or treating bone disease, comprising an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 6.
11. A composition for preventing or treating bone disease in claim 10, wherein the bone disease is at least one selected from the group consisting of osteoporosis, periodontal disease, rheumatoid arthritis, multiple myeloma, degenerative arthritis, inflammatory alveolar bone resorption disease, and inflammatory bone resorption disease.
12. A method for preventing or treating bone disease, comprising administering to a subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6.
13. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1 to 6 for the prevention or treatment of bone disease.
Citation Information
Patent Citations
Vaspin, a biomarker for diagnosing metabolic disease
KR100875301B1
Myeloma biomarker serpinf2 and use thereof
WO2023004626A1
